Wells Fargo & Company MN Has $187,000 Stake in Athersys, Inc. (ATHX)
Wells Fargo & Company MN raised its stake in Athersys, Inc. (NASDAQ:ATHX) by 102.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 123,576 shares of the biopharmaceutical company’s stock after acquiring an additional 62,400 shares during the quarter. Wells Fargo & Company MN owned approximately 0.11% of Athersys worth $187,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ATHX. Bank of America Corp DE grew its position in shares of Athersys by 17.2% in the first quarter. Bank of America Corp DE now owns 61,580 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 9,019 shares during the period. SG Americas Securities LLC grew its position in shares of Athersys by 329.7% in the second quarter. SG Americas Securities LLC now owns 73,434 shares of the biopharmaceutical company’s stock valued at $111,000 after purchasing an additional 56,345 shares during the period. State of Wisconsin Investment Board purchased a new stake in shares of Athersys in the second quarter valued at $113,000. Blair William & Co. IL grew its position in shares of Athersys by 708.0% in the second quarter. Blair William & Co. IL now owns 80,804 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 70,804 shares during the period. Finally, Rhumbline Advisers grew its position in shares of Athersys by 34.2% in the second quarter. Rhumbline Advisers now owns 110,064 shares of the biopharmaceutical company’s stock valued at $166,000 after purchasing an additional 28,030 shares during the period. 19.94% of the stock is owned by institutional investors.
Shares of Athersys, Inc. (NASDAQ:ATHX) opened at $2.00 on Thursday. Athersys, Inc. has a 1 year low of $1.02 and a 1 year high of $2.63.
ATHX has been the subject of a number of recent analyst reports. Maxim Group set a $12.00 price objective on Athersys and gave the company a “buy” rating in a research report on Thursday, October 5th. Zacks Investment Research raised Athersys from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a research report on Thursday, September 7th. Finally, ValuEngine downgraded Athersys from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Athersys presently has a consensus rating of “Buy” and a consensus target price of $7.17.
In other Athersys news, insider William Lehmann, Jr. sold 15,000 shares of the business’s stock in a transaction dated Tuesday, September 19th. The stock was sold at an average price of $2.38, for a total transaction of $35,700.00. Following the completion of the sale, the insider now owns 527,380 shares of the company’s stock, valued at $1,255,164.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 9.40% of the stock is currently owned by insiders.
Athersys Company Profile
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.